Erytech Pharma S.A. (ERYP) News
Filter ERYP News Items
ERYP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ERYP News From Around the Web
Below are the latest news stories about ERYTECH PHARMA SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net ( |
Monthly information related to total number of voting rights and shares composing the share capital _November 30, 2022Monthly information related to total number of voting rights and shares composing the share capital _November 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022ERYTECH Provides Business and Financial Update for the Third Quarter of 2022 Conference call and webcast on Tuesday, November 22, 2022at 8:30am ET / 02:30pm CET Lead program Graspa halted Focus on preclinical programs and partnering optionsDeep restructuring implemented; team size reduced by approximately 75% since start of year Cash and cash equivalents of €47.3 million ($46.3 million) at the end of September 2022 Cambridge, MA (U.S.) and Lyon (France), November 21, 2022 – ERYTECH Pharma (Nasda |
ERYTECH Announces Receipt of Nasdaq NoticeERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated October 7, 2022, indicating that, based upon a closing bid price of less than $1.00 per |
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's WhyErytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
ERYTECH Provides Business and Financial Update for the First Half of 2022ERYTECH Provides Business and Financial Update for the First Half of 2022 Conference call and webcast on Tuesday, September 13, 2022at 8:30am ET / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent in April 2022Evaluation of partnering options ongoing, strategic initiative expected in Q4 2022Plans to pursue a BLA submission for Graspa® in hypersensitive ALL stopped Cash and cash equivalents of €53.3 million ($55.8 million) at the end of June 2022 Cambridge, MA (U.S.) and Lyon |
Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) |
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2 |
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform. |